These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6791550)

  • 21. Interactions of human mast cell tryptase with biological protease inhibitors.
    Alter SC; Kramps JA; Janoff A; Schwartz LB
    Arch Biochem Biophys; 1990 Jan; 276(1):26-31. PubMed ID: 1688695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.
    Nagasawa K; Uchiyama H
    J Biochem; 1984 Mar; 95(3):619-26. PubMed ID: 6725227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding.
    Huntington JA; Olson ST; Fan B; Gettins PG
    Biochemistry; 1996 Jul; 35(26):8495-503. PubMed ID: 8679610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule.
    Niewiarowski S; Rucinski B; James P; Lindahl U
    FEBS Lett; 1979 Jun; 102(1):75-8. PubMed ID: 456593
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity.
    Olson ST; Frances-Chmura AM; Swanson R; Björk I; Zettlmeissl G
    Arch Biochem Biophys; 1997 May; 341(2):212-21. PubMed ID: 9169007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin binding domain of antithrombin III: characterization using a synthetic peptide directed polyclonal antibody.
    Smith JW; Dey N; Knauer DJ
    Biochemistry; 1990 Sep; 29(38):8950-7. PubMed ID: 2271570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further characterization of dextran sulfate as a cofactor of protein C inhibitor.
    Kazama Y; Koide T; Sakuragawa N
    Thromb Res; 1989 Jun; 54(5):499-504. PubMed ID: 2475920
    [No Abstract]   [Full Text] [Related]  

  • 29. The molecular mechanisms of heparin action: II. Separation of functionally different heparins by affinity chromatography.
    Walker FJ; Esmon CT
    Thromb Res; 1979 Jan; 14(1):219-30. PubMed ID: 570741
    [No Abstract]   [Full Text] [Related]  

  • 30. Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III.
    Edens RE; Fromm JR; Fromm SJ; Linhardt RJ; Weiler JM
    Biochemistry; 1995 Feb; 34(8):2400-7. PubMed ID: 7873519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites.
    Piepkorn MW
    Biochem J; 1981 May; 196(2):649-51. PubMed ID: 7317004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the domain structure of antithrombin III. Tentative localization of the heparin binding region using 1H NMR spectroscopy.
    Gettins P; Wooten EW
    Biochemistry; 1987 Jul; 26(14):4403-8. PubMed ID: 3663595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinity.
    Mushunje A; Zhou A; Huntington JA; Conard J; Carrell RW
    Thromb Haemost; 2002 Sep; 88(3):436-43. PubMed ID: 12353073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the strength of binding of antithrombin III, protamine and poly(L-lysine) to heparin samples of different anticoagulant activities.
    Jones GR; Hashim R; Power DM
    Biochim Biophys Acta; 1986 Aug; 883(1):69-76. PubMed ID: 3730427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction between heparin and antithrombin III: a comparison of two different heparin-dye conjugates.
    Jones GR; Hashim R; Power DM
    Biochim Biophys Acta; 1987 Jul; 925(1):57-62. PubMed ID: 3109497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction of protein-bound heparin and antithrombin III.
    Shanberge JN; Sridhar CN
    Ann N Y Acad Sci; 1981; 370():708-13. PubMed ID: 6168228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphate promotes glycation of antithrombin III which interferes with heparin binding.
    Hall PK; Roberts RC
    Biochim Biophys Acta; 1989 Dec; 993(2-3):217-23. PubMed ID: 2597694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial binding sites for heparin. Specificity and role in heparin neutralization.
    Bârzu T; Van Rijn JL; Petitou M; Molho P; Tobelem G; Caen JP
    Biochem J; 1986 Sep; 238(3):847-54. PubMed ID: 2432885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of heparin on the glia-derived-nexin-thrombin interaction.
    Wallace A; Rovelli G; Hofsteenge J; Stone SR
    Biochem J; 1989 Jan; 257(1):191-6. PubMed ID: 2920011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence that arginine-129 and arginine-145 are located within the heparin binding site of human antithrombin III.
    Sun XJ; Chang JY
    Biochemistry; 1990 Sep; 29(38):8957-62. PubMed ID: 2271571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.